Please upgrade your browser.
Despite many waves of debate and piecemeal reforms, the U.S. health care system remains largely the same as it was decades ago. We have seen no convincing approach to changing the unsustainable trajectory of the system, much less to offsetting the rising costs of an aging population and new medical advances.
Earn $50 while helping edit questionnaire about RCC treatment preferences
Please join Congressman Paul Ryan (WI), a national leader on health care reform, and Heritages Bob Moffit for a special tele-town hall on Tuesday, June 9, 2009 at 7pm ET.
ASONEP, as a single agent in naïve mice, significantly delays the progression of disease in a mouse model of renal cell carcinoma (RCC). The delay in disease progression was about 60% longer than the delay typically seen in this same model with VEGF-Receptor-Tyrosine-Kinase Inhibitors (TKIs).
GlaxoSmithKline (GSK) announced the results of a Phase III study demonstrating that pazopanib reduced the risk of tumor progression or death by 54%.
Antigenics said patients with kidney cancer at intermediate risk of disease recurrence showed about 46 percent lower risk of death when treated with the cancer vaccine, Oncophage.
John Powis, who suffered from kidney cancer, died at Yeovil District Hospital on 18 July last year when his heart failed due to the side-effects of Sunitinib.
Congress is poised to pass one of the worst public health laws ever conceived.
Its happening all the time. Nearly every day, there are new reports of counterfeit drugs flooding the worlds prescription drug market.
Health reform will be expensive. Just how expensive partly has to do with how we choose to finance it. Joseph Antos argues against limiting income tax deduction in favor of capping or eliminating the deduction for employer-sponsored health insurance, as the latter would do more to bend the cost-growth curve of health care going forward.
|Powered by NeonCRM|